Pharmaceutical News

RSS

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

Genmed obtains marketing authorization license for paracetamol in Europe

Genmed Holding Corp. is announcing its entry into the European generic drug market with the receipt of its first marketing and distribution license for paracetamol. Also known as acetaminophen, paracetamol is an over-the-counter drug used to treat mild to moderate pain from headaches, backaches, osteoarthritis, and to reduce fever.

22 Dec 2010

3M sues Andover for patent infringement over two layer compression bandage systems

3M and 3M Innovative Properties Co. filed a lawsuit in the U.S. District Court for the District of Minnesota today against Andover Healthcare Inc. seeking a preliminary injunction as well as a permanent injunction and damages regarding Andover's two layer compression bandage systems.

22 Dec 2010

Exercise and Vitamin D supplementation most effective in reducing fall among seniors

A systematic review of over 50 clinical trials finds that exercise and Vitamin D supplements are the best ways to reduce the risk of falling in people aged 65 and over. The review is published in the December 21 issue of Annals of Internal Medicine and was commissioned by the US Preventive Services Task Force.

22 Dec 2010

Today's Opinions: The collective benefits of the new health law; Patient safety; Legalizing marijuana

If President Obama's reform package remains intact, [cancer patient Michelle] Mindlin will be able to shop for potentially more affordable coverage in an insurance "exchange" where companies will be prevented from turning people away because of their medical history. But that doesn't go into effect until 2014. And it might not happen at all if the courts overturn a requirement that nearly everyone buy health insurance (David Lazarus, 12/21).

21 Dec 2010

AIDS Healthcare Foundation sues AIDS drug maker for overcharging

AIDS Healthcare Foundation (AHF) will host a press teleconference on Wednesday, December 22nd at 9:30 AM Pacific/12:30 PM Eastern to announce that it has filed a lawsuit against Johnson & Johnson’s Tibotec Therapeutics for overcharging AHF for AIDS drugs purchased under the 340B program.

21 Dec 2010

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

In its recently released annual 2010 update, ChartTrends®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer biologic agents such as UCB's Cimzia and Centocor OrthoBiotech's Simponi, although lagging in overall market share, have begun to penetrate the first line biologic position primarily at the expense of Pfizer/Amgen's Enbrel and Abbott's Humira.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Researchers develop new malaria vaccine strategy based on ingestion of genetically modified starch

Researchers from two laboratories in northern France have successfully vaccinated and protected mice by feeding them starch derived from green algae and genetically modified to carry vaccine proteins.

21 Dec 2010

Auspex, Teva Pharmaceutical to develop deuterium-containing drug

Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.

21 Dec 2010

New predictive medicine product for hereditary pancreatic and related cancers

Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.

21 Dec 2010

EpiCept receives Israeli Ministry of Health approval for Ceplene

EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.

21 Dec 2010

PharMEDium introduces pre-labeled, ready-to-use Propofol in tamper evident syringe admixture system

PharMEDium Services LLC, announced the addition of Propofol to its custom operating room anesthesia syringe preparation services. PharMEDium is the first compounder to offer Propofol in a pre-labeled, single patient, ready-to-use, tamper evident syringe admixture system. Healthcare organizations recognize benefits of PharMEDium's prefilled operating room syringes including compliance with regulatory requirements for proper labeling of all medications, and improved economic efficiency by reducing waste.

21 Dec 2010

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

Hemispherx Biopharma, Inc. announced that the Company has entered into an agreement with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA for the marketing of Alferon N Injection®, the Company's natural interferon injection product which has been FDA approved for a category of sexually transmitted diseases in Argentina with an option for other Latin American countries upon receipt of those respective countries' regulatory approval for any use of the product.

21 Dec 2010

Lilly completes acquisition of Avid

Eli Lilly and Company today announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on November 8, 2010, has received the approval of Avid stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.

20 Dec 2010

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

AstraZeneca’s new blood thinner that was pitched against Plavix, the world’s second-best selling drug failed to live up to expectations making stocks drop to a two year low, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.

20 Dec 2010

Forest acquires all rights held by Gruenenthal for colistin

The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.

20 Dec 2010

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.

20 Dec 2010

Pharmaceutical News

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Genmed obtains marketing authorization license for paracetamol in Europe

3M sues Andover for patent infringement over two layer compression bandage systems

Exercise and Vitamin D supplementation most effective in reducing fall among seniors

Today's Opinions: The collective benefits of the new health law; Patient safety; Legalizing marijuana

AIDS Healthcare Foundation sues AIDS drug maker for overcharging

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

Gilenya offers more benefits for MS therapy than previously realized

Researchers develop new malaria vaccine strategy based on ingestion of genetically modified starch

Auspex, Teva Pharmaceutical to develop deuterium-containing drug

New predictive medicine product for hereditary pancreatic and related cancers

EpiCept receives Israeli Ministry of Health approval for Ceplene

PharMEDium introduces pre-labeled, ready-to-use Propofol in tamper evident syringe admixture system

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

Lilly completes acquisition of Avid

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

Forest acquires all rights held by Gruenenthal for colistin

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News